Yahoo Finance • 2 months ago
Alector, Inc. --Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Lato... Full story
Yahoo Finance • 4 months ago
Alector (NASDAQ:ALEC) Second Quarter 2024 Results Key Financial Results Revenue: US$15.1m (down 73% from 2Q 2023). Net loss: US$38.7m (down from US$1.38m profit in 2Q 2023). US$0.40 loss per share (down from US$0.016 profit in 2Q 2023).... Full story
Yahoo Finance • 10 months ago
Alector, Inc. The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE... Full story
Yahoo Finance • 11 months ago
Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time. Continue reading... Full story
Yahoo Finance • 12 months ago
SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the C... Full story
Yahoo Finance • last year
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel... Full story
Yahoo Finance • last year
Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants Enrollment completed in the INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer’... Full story
Yahoo Finance • last year
--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today annou... Full story
Yahoo Finance • 2 years ago
With a price-to-sales (or "P/S") ratio of 4.2x Alector, Inc. (NASDAQ:ALEC) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United States have P/S ratios greater than 11.5x and... Full story
Yahoo Finance • 2 years ago
SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a corporate presentation at th... Full story
Yahoo Finance • 2 years ago
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming... Full story
Yahoo Finance • 2 years ago
On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024 Preparing to engage with regulatory authorities in mid-2023 and t... Full story
Yahoo Finance • 2 years ago
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN,... Full story
Yahoo Finance • 2 years ago
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on November 1, 2022, the com... Full story
Yahoo Finance • 2 years ago
Promotion demonstrates Alector’s commitment tobuilding a world-class culture that questions convention, embraces feedback and promotes development for all employees Company recently earned the Great Place to Work® certification for the th... Full story
Yahoo Finance • 2 years ago
AbbVie Inc (NYSE: ABBV) has decided to terminate the CD33 collaboration program with Alector Inc (NASDAQ: ALEC), developing AL003 for Alzheimer’s disease as one of two programs under the co-development and option agreement. As previously d... Full story
Yahoo Finance • 2 years ago
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldma... Full story
Yahoo Finance • 3 years ago
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the BofA Se... Full story
Yahoo Finance • 3 years ago
NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC), Reata Pharmaceuticals, Inc. (NASDAQ: R... Full story
Yahoo Finance • 3 years ago
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medic... Full story